Levothyroxine to increase live births in euthyroid women with thyroid antibodies trying to conceive: the TABLET RCT

Rima K Dhillon-Smith,1,2,3 Lee J Middleton,4 Kirandeep K Sunner,4 Versha Cheed,4 Krys Baker,5 Samantha Farrell-Carver,4 Ruth Bender-Atik,6 Rina Agrawal,7 Kalsang Bhatia,8 Edmond Edi-Osagie,9 Tarek Ghobara,7 Pratima Gupta,10 Davor Jurkovic,11 Yacoub Khalaf,12 Marjory MacLean,13 Chris McCabe,1 Khashia Mulbagal,14 Natalie Nunes,15 Caroline Overton,16 Siobhan Quenby,7 Rajendra Rai,17 Nick Raine-Fenning,18,19 Lynne Robinson,3 Jackie Ross,20 Andrew Sizer,21 Rachel Small,9 Alex Tan,22 Martyn Underwood,21 Mark D Kilby,1,3 Kristien Boelaert,1 Jane Daniels,23 Shakila Thangaratinam,22 Shiao-Yng Chan24 and Arri Coomarasamy1,2,3*

1Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
2Tommy’s Centre for Miscarriage Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
3Centre for Women’s and Newborn Health, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UK
4Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
5Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
6The Miscarriage Association, Wakefield, UK
7University Hospital Coventry, University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK
8Burnley General Hospital, East Lancashire Hospitals NHS Trust, Burnley, UK
9Saint Mary’s Hospital, Manchester University NHS Foundation Trust, Manchester, UK
10Birmingham Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
Scientific summary

The TABLET RCT
Efficacy and Mechanism Evaluation 2019; Vol. 6: No. 11
DOI: 10.3310/eme06110

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background
Thyroid autoantibodies, specifically thyroid peroxidase antibodies, have been strongly associated with miscarriage and preterm birth in women with a normal thyroid function. Two small randomised controlled trials showed a reduction in adverse pregnancy outcomes with levothyroxine.

Objectives
The Thyroid AntiBodies and LEvoThyroxine (TABLET) trial was designed to test the hypothesis that, in euthyroid women with thyroid peroxidase antibodies, 50 µg of levothyroxine taken once daily from the point of preconception and continued until the end of pregnancy, compared with placebo, would increase live births beyond 34 completed weeks of pregnancy by at least 10%. A concurrent mechanistic study was conducted to examine if the effect of levothyroxine may be mediated by changes in immune responses.

Design
This was a randomised, double-blind, placebo-controlled, multicentre trial with a mechanistic element to explore causality.

Setting
The trial was conducted in hospital settings across the UK, recruiting from 49 sites between 2011 and 2016.

Participants
Women with a normal thyroid function and with thyroid peroxidase antibodies who were aged between 16 and 41 years, trying for a pregnancy either naturally or through assisted conception, and willing and able to give informed consent were eligible. Women were recruited from three main settings: early pregnancy units following a miscarriage, infertility clinics/assisted conception units and recurrent miscarriage clinics. For the purpose of the trial, women were given a 12-month time frame in which to conceive from randomisation.

Interventions
Each participant in the TABLET trial received either levothyroxine at a dose of 50-µg capsules daily or placebo capsules daily. These were commenced as soon as randomised preconceptually, and continued until the end of a pregnancy, regardless of the timing of the end of the pregnancy. Neither the clinician nor the patient knew which group they were allocated to throughout the trial.

Main outcome measures
The primary outcome was live birth at or beyond 34 completed weeks of gestation. The secondary outcomes included miscarriage; clinical pregnancy at 7 weeks; ongoing pregnancy at 12 weeks; gestation at delivery; mode of delivery; birthweight; appearance, pulse, grimace, activity and respiration (Apgar) scores; congenital abnormalities; and neonatal survival at 28 days of life.
Methods

Randomisation was performed preconceptually following confirmation of normal thyroid function tests and positivity for thyroid peroxidase antibodies. Participants were randomised in a 1 : 1 ratio. Minimisation was implemented for age (< 35 or ≥ 35 years), number of previous miscarriages (0, 1 or 2, ≥ 3), baseline thyroid-stimulating hormone concentration (≤ 2.5 or > 2.5 mIU/l) and infertility treatment (yes/no) to achieve balanced trial arms. For logistical reasons, the randomisation was also minimised by centre. Randomisation was performed online via a secure internet facility. Women were followed up every 3 months while trying to conceive to check thyroid function and general well-being; once pregnant, they were seen each trimester: 6–8 weeks, 16–18 weeks and 28 weeks. Following delivery, a follow-up telephone call was made after 28 days to assess neonatal outcome. Any abnormal thyroid results were managed appropriately in line with local clinical guidance at the time.

A subset of women were recruited to provide additional serum samples longitudinally for the assessment of 17 different chemocytokines by multiplex enzyme-linked immunosorbent assays.

Results

A total of 19,556 participants were screened for eligibility, with thyroid peroxidase antibody positivity found in 9.5% of participants (1827/19,237). A total of 1420 women were eligible for participation, of whom 952 were randomised between 2011 and 2016; 476 received levothyroxine and 476 received placebo. However, six women from each arm were either withdrawn or lost to follow-up, and so outcome data were available for only 470 in each group. A total of 540 women achieved a pregnancy in the 12-month time frame: 266 women conceived in the levothyroxine arm and 274 in the placebo arm. The baseline data (i.e. age, body mass index, maternal ethnicity, smoking status and parity) of the participants were comparable in the two arms of the trial. The follow-up rate to primary outcome was 940 out of 952 participants (98.7%).

The live birth rate in the levothyroxine group was 37% (176/470) and the rate in the placebo group was 38% (178/470), translating to a relative risk of 0.97 (95% confidence interval 0.83 to 1.14; p = 0.74) and an absolute risk difference of –0.4% (95% confidence interval –6.6% to 5.8%).

There was no evidence of a significant difference between the groups for any of the secondary outcomes:

- clinical pregnancy at 7 weeks of gestation – levothyroxine group 89% (237/266) versus placebo group 91% (248/274); relative risk 0.98, 95% confidence interval 0.93 to 1.04; p = 0.59
- ongoing pregnancy at 12 weeks of gestation – levothyroxine group 73% (194/266) versus placebo group 73% (200/274); relative risk 1.00, 95% confidence interval 0.90 to 1.11; p = 0.99
- miscarriage at < 24 weeks – levothyroxine group 28% (75/266) versus placebo group 30% (81/274); relative risk 0.95, 95% confidence interval 0.73 to 1.23; p = 0.68
- ectopic pregnancy – levothyroxine group 1% (3/266) versus placebo group 2% (6/274); relative risk 0.50, 95% confidence interval 0.13 to 1.99; p = 0.33
- stillbirth – levothyroxine group 0.4% (1/266) versus placebo group 0% (0/274)
- gestation at delivery – levothyroxine group 38+6 versus placebo group 39+0; p = 0.65
- birthweight (g) – levothyroxine group 3226 (standard deviation 660) versus placebo group 3262 (standard deviation 668); p = 0.60
- no early or late neonatal deaths in either group.

The subset of 49 women (26 in levothyroxine arm and 23 in placebo arm) recruited into the mechanistic study demonstrated that treatment with levothyroxine resulted in some changes in chemocytokine concentrations in the non-pregnant state and in very early pregnancy, but these changes had no bearing on whether or not the pregnancy resulted in a live birth outcome.
Conclusions

The TABLET trial is the largest prospective randomised clinical trial conducted on the subject of thyroid antibodies and pregnancy loss, to our knowledge. The trial was appropriately sized and methodologically robust to conclude that levothyroxine commenced preconceptually in euthyroid women with thyroid peroxidase antibodies is of no benefit. One of the limitations of the trial is that we did not look to explore titrations of levothyroxine dose based on body weight or thyroid-stimulating hormone or thyroid peroxidase antibody concentration. Furthermore, the trial did not explore the effects of levothyroxine in women with subclinical hypothyroidism. Future work could investigate the effectiveness of preconceptual levothyroxine treatment to reduce adverse pregnancy outcomes for women with subclinical hypothyroidism, with or without thyroid peroxidase antibodies. This is currently a particular area of controversy in the subfertility population.

Trial registration

This trial is registered as Current Controlled Trials ISRCTN15948785 and EudraCT 2011-000719-19.

Funding

This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership.
Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutic or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

This report

The research reported in this issue of the journal was funded by the EME programme as project number 09/100/10. The contractual start date was in June 2011. The final report began editorial review in June 2018 and was accepted for publication in November 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2019. This work was produced by Dhillon-Smith et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).